Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1979-11-21
|
pubmed:abstractText |
Measurements of beta-endorphin-like immunoreactivity have been performed in CSF and plasma of patients with schizophrenia and other neuropsychiatric disorders. The detection limit of the RIA was between 20--50 pg/ml (6--15 fmole/ml). In CSF the quantity of beta-endorphin-like immunoreactivity ranges up to 65 pg/ml. The data from schizophrenics and other neuropsychiatric patients show no obvious deviation from the results in a control group of medical patients with normal CSF findings. In plasma the immunoreactive beta-endorphin-like material ranges up to 250 pg/ml. There is only a small tendency to higher values in schizophrenic patients, if compared with different types of neuroses and affective and organic psychoses. In a second series of experiments also this tendency could not be reproduced. In 9 electroconvulsive treatments an increase of blood beta-endorphin-like immunoreactivity was observed 7 times. A possible endorphinergic mechanism in the mode of action of electroconvulsion is hypothesized.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0031-7098
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
12
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
269-76
|
pubmed:dateRevised |
2009-11-11
|
pubmed:meshHeading |
pubmed-meshheading:482350-Adolescent,
pubmed-meshheading:482350-Adult,
pubmed-meshheading:482350-Aged,
pubmed-meshheading:482350-Endorphins,
pubmed-meshheading:482350-Female,
pubmed-meshheading:482350-Humans,
pubmed-meshheading:482350-Male,
pubmed-meshheading:482350-Middle Aged,
pubmed-meshheading:482350-Psychotic Disorders,
pubmed-meshheading:482350-Radioimmunoassay,
pubmed-meshheading:482350-Schizophrenia
|
pubmed:year |
1979
|
pubmed:articleTitle |
beta-Endorphin-like immunoreactivity in cerebrospinal fluid and plasma of patients with schizophrenia and other neuropsychiatric disorders.
|
pubmed:publicationType |
Journal Article
|